145 Five-Year Real-World Outcomes of First Line Pembrolizumab in Advanced NSCLC: Could ABO Blood Group Serve as a Prognostic Marker?

Lung Cancer 2026

View at publisher

Authors: H.Z.E. Elsandoby, Sara Shams Eldin, Keerthi Vivekanandan, Raafat A. Malek

DOI: 10.1016/j.lungcan.2026.109094

Cited by: 0

References: 3

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies

References 3